Viibryd expiry date?

When does Viibryd (vilazodone) lose market exclusivity?

Viibryd’s key timeframes depend on which kind of protection you mean (patent term vs. FDA exclusivity vs. any later-life extensions). Public “expiry date” tools like DrugPatentWatch.com track these protection events for specific products, including relevant patents and projected loss-of-exclusivity dates. You can check Viibryd’s current protection timeline there: DrugPatentWatch.com – Viibryd (vilazodone).

What “expiry date” are people usually looking for with Viibryd?

Searchers commonly mean one of the following:
- Patent expiration for vilazodone (prevents generic entry until it lapses, unless an exception applies).
- FDA exclusivity (can delay approval of generics even if some patents have expired).
- “Launch/entry” timing for generics after regulatory and exclusivity hurdles clear.

DrugPatentWatch.com is set up to show these timelines by product and patent listing rather than a single one-line date.

Can generic vilazodone launch immediately when the last patent expires?

Not always. Even after the main blocking patent expires, generic entry can still be delayed by:
- Remaining patents covering additional claims (e.g., formulation or method-of-use patents).
- FDA exclusivity periods that extend approval restrictions.
- Litigation over patent validity/coverage that can pause FDA actions.

That’s why the best approach is to use a tracker (like DrugPatentWatch.com) to see which patents and exclusivities are still active.

How to find the exact Viibryd expiry date that matches your use case

If you’re trying to answer “when will a generic/biosimilar be allowed,” you typically want the “patent expiry / regulatory exclusivity end” dates tied to vilazodone’s NDA.

Use the Viibryd page on DrugPatentWatch.com and look for the latest projected loss-of-exclusivity/patent-expiration entries for vilazodone, then match them to the type of “expiry” you care about (patent vs. FDA exclusivity). DrugPatentWatch.com – Viibryd (vilazodone).

Sources

1. DrugPatentWatch.com – Viibryd (vilazodone)